Skip to content

Comparison of ruby fractional laser and Q-switched Nd:YAG laser for the treatment of melasma: A randomized, self-controlled, split-face study

Comparison of ruby fractional laser and Q-switched Nd:YAG laser for the treatment of melasma: A randomized, self-controlled, split-face study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056389
Enrollment
Unknown
Registered
2022-02-04
Start date
2022-02-01
Completion date
Unknown
Last updated
2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma

Interventions

treatment group:ruby fractional laser
control group:Q-Switched Nd:YAG Laser

Sponsors

Department of Dermatology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Female, aged 18 to 50 years; 2. Meeting the diagnostic criteria for melasma in the "Diagnostic Criteria for Melasma and Vitiligo (2010 Edition)"; 3. Symmetrically distributed on the face with similar degree, extent and color; 4. Patients agree to participate in the study and sign the Informed Consent Form.

Exclusion criteria

Exclusion criteria: 1. Patients with chronic skin diseases or skin tumors on the face; 2. Laser treatment is contraindicated (e.g. patients with photosensitive dermatoses, photo-aggravated dermatoses, light-related skin malignancies, and photosensitive drug takers, etc.); 3. Patients received other treatments within 6 months (including but not limited to drugs, lasers, intense pulsed light, mesotherapy, chemical peels and other therapeutic measures); 4. Patients with serious liver, kidney, cardiovascular, respiratory, hematopoietic diseases and malignant tumors; 5. Pregnancy and lactation; 6. Patients who are taking anticoagulants, contraceptives, sex hormones, thyroxine and other drugs, which may affect the assessment of efficacy; 7. Patients who cannot protect themselves from the sun and light after therapy; 8. Patients with mental illness; 9. Patients who are unwilling to provide medical history information or do not accept follow-up; 10. There are other conditions that the investigator considers unsuitable for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
Modified Melasma area severity index;

Secondary

MeasureTime frame
Physician Global Assessment;Patient satisfaction;Safety evaluation;

Countries

China

Contacts

Public ContactZhao Yi

Department of Dermatology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University

zhaoyimd@mail.tsinghua.edu.cn+86 13718646181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026